Deforolimus: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Deforolimus": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
Line 1: | Line 1: | ||
{{CMG}} | {{CMG}} | ||
'''Deforolimus''' (also known as '''AP23573''' and '''MK-8669''') is an immunosupressant currently undergoing research for the treatment of certain cancers. It is a small-molecule inhibitor of the [[mammalian target of rapamycin]] (mTOR). Blocking mTOR creates a starvation-like effect in cancer cells by interfering with [[cell growth]], [[cell division|division]], [[metabolism]], and [[angiogenesis]]. | '''Deforolimus''' (also known as '''AP23573''' and '''MK-8669''') is an immunosupressant currently undergoing research for the treatment of certain cancers. It is a small-molecule inhibitor of the [[mammalian target of rapamycin]] (mTOR). Blocking mTOR creates a starvation-like effect in cancer cells by interfering with [[cell growth]], [[cell division|division]], [[metabolism]], and [[angiogenesis]]. |
Latest revision as of 00:33, 9 August 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Deforolimus (also known as AP23573 and MK-8669) is an immunosupressant currently undergoing research for the treatment of certain cancers. It is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR). Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.
Deforolimus is being co-developed by Merck and ARIAD Pharmaceuticals. As of 2008, a phase III clinical trial of deforolimus in metastatic soft-tissue and bone sarcomas responsive to chemotherapy, SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus), is recruiting patients.[1][2]
References
- ↑ "SUCCEED: Landmark Global Phase 3 Trial Now Enrolling!". ARIAD Pharmaceuticals. 2008. Retrieved 2008-04-18.
- ↑ Deforolimus (AP23573) in Treatment of Sarcoma - SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus) Study. ClinicalTrials.gov (2008-03-07). Retrieved on 2008-04-18.